Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN9708 and Vorinostat in Advanced p53 Mutant Malignancies
NCT02042989Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2014
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in solid tumor and lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Doses of MLN9708 and Vorinostat. Started Jun 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT02042989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042989.